CClinicalTrials.gg
WithdrawnNCT03398252Updated Sep 1, 2022

Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL

A Phase 1 interventional study of Doxazosin XL and Placebo in Alcohol Use Disorder, sponsored by The University of Texas Health Science Center, Houston. Withdrawn. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-09-01.

Sponsored by The University of Texas Health Science Center, Houston · Phase 1, Interventional, and Other

Why this study was withdrawn
No funding
Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

Participants (N=10/group) will consist of non-treatment seeking individuals with AUD.

Following informed consent and baseline screening, participants will partake in 3 stress induction sessions to assess their stress levels and cravings for alcohol. Participants will be randomized to receive either increasing doses of doxazosin XL (0, 4, and 8 mg) or placebo in a double-blind manner.

02

Conditions studied

  • Alcohol Use Disorder

Browse trials for

03

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Meet DSM-5 criteria for AUD;
  • Report excessive alcohol use as defined by CDC guidelines in the past month (>7 drinks/week for woman, >14 drinks/week for men, >3 drinks/occasion for women>4 drinks/occasion for men)3.

Exclusion criteria

Exclusion Criteria:

  • Physical dependence on alcohol assessed using the SCID and Clinical Institute Withdrawal Assessment for Alcohol (CIWAA)41.
  • Presenting an Alcohol Use Disorders Inventory (AUDIT) score indicative of severe alcohol dependence (≥13 for women, ≥15 for men);
  • Meeting criteria for substance use disorder on drugs other than alcohol and nicotine;
  • Currently taking a prescribed psychoactive medication (e.g., atomoxetine for ADHD). In addition, exclusion for those individuals taking CYP3A4 inhibitors. Most participants will not be taking any concomitant medications (including over-the-counter supplements). For those who are taking an allowed medication, the study physician will determine if the medications are CYP3A4 inhibitors.
  • Medical conditions contraindicating doxazosin XL pharmacotherapy (e.g., postural hypotension);
  • Taking contraindicated medications such as blood pressure medications;
  • Be pregnant, nursing, or planning on becoming pregnant during the course of the study;
  • Have any other illness, condition, or use of medications, which in the opinion of the PI and/or admitting physician would preclude safe and/or successful completion of the study.
04

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Doxazosin XL

    Participants will receive increasing doses of doxazosin XL (0, 4, and 8 mg).

    Drug: Doxazosin XL

  • Placebo comparator
    Placebo

    Participants will be randomized to receive a placebo for doxazosin XL.

    Drug: Placebo

Interventions

  • DrugDoxazosin XL

    Participants will be randomized to receive increasing doses of doxazosin XL (0, 4, and 8 mg).

    Also known as: Cardura XL, Cardura

  • DrugPlacebo

    Participants will be randomized to receive a placebo for doxazosin XL.

05

What researchers measure

Primary outcomes

  1. Feasibility as study attendance

    Attending sessions

    Time frame: Two weeks

Secondary outcomes

  1. Stress as assessed by salivary cortisol levels

    Cortisol levels will be measured using the Cortisol ELISA Kit (Enzo Life Sciences).

    Time frame: baseline

  2. Stress as assessed by salivary cortisol levels

    Cortisol levels will be measured using the Cortisol ELISA Kit (Enzo Life Sciences).

    Time frame: Friday of week 1

  3. Stress as assessed by salivary cortisol levels

    Cortisol levels will be measured using the Cortisol ELISA Kit (Enzo Life Sciences).

    Time frame: Friday of week 2

  4. Stress as assessed by self-report

    Self-reported stress on a questionnaire

    Time frame: baseline

  5. Stress as assessed by self-report

    Self-reported stress on a questionnaire

    Time frame: Friday of week 1

  6. Stress as assessed by self-report

    Self-reported stress on a questionnaire

    Time frame: Friday of week 2

  7. Stress as assessed by heart rate

    Self-reported stress on a questionnaire

    Time frame: baseline

  8. Stress as assessed by heart rate

    Self-reported stress on a questionnaire

    Time frame: Friday of week 1

  9. Stress as assessed by heart rate

    Self-reported stress on a questionnaire

    Time frame: Friday of week 2

  10. stress reactivity as assessed by increased blood pressure

    Blood pressure

    Time frame: baseline

  11. stress reactivity as assessed by increased blood pressure

    Blood pressure

    Time frame: Friday of week 1

  12. stress reactivity as assessed by increased blood pressure

    Blood pressure

    Time frame: Friday of week 2

  13. Alcohol craving as assessed by the Penn Alcohol Craving Scale (PACS)

    The Penn Alcohol Craving Scale (PACS) is a 5 question self-report measure that assesses alcohol craving in the past week. Each question ranges from 0 (no craving) to 6 (highest craving). The total score on the scale ranges from 0 to 30, and higher scores indicate greater alcohol craving.

    Time frame: baseline

  14. Alcohol craving as assessed by the Penn Alcohol Craving Scale (PACS)

    The Penn Alcohol Craving Scale (PACS) is a 5 question self-report measure that assesses alcohol craving in the past week. Each question ranges from 0 (no craving) to 6 (highest craving). The total score on the scale ranges from 0 to 30, and higher scores indicate greater alcohol craving.

    Time frame: Friday of week 1

  15. Alcohol craving as assessed by the Penn Alcohol Craving Scale (PACS)

    The Penn Alcohol Craving Scale (PACS) is a 5 question self-report measure that assesses alcohol craving in the past week. Each question ranges from 0 (no craving) to 6 (highest craving). The total score on the scale ranges from 0 to 30, and higher scores indicate greater alcohol craving.

    Time frame: Friday of week 2

  16. Alcohol Demand as assessed by the Brief Assessment of Alcohol Demand (BAAD) questionnaire

    Alcohol demand will be assessed via the Brief Assessment of Alcohol Demand (BAAD), a 3-item questionnaire ("If drinks were free, how many would have?", "What is the maximum total amount you would spend on drinking?"; and "What is the maximum you would pay for a single drink?").

    Time frame: baseline

  17. Alcohol Demand as assessed by the Brief Assessment of Alcohol Demand (BAAD) questionnaire

    Alcohol demand will be assessed via the Brief Assessment of Alcohol Demand (BAAD), a 3-item questionnaire ("If drinks were free, how many would have?", "What is the maximum total amount you would spend on drinking?"; and "What is the maximum you would pay for a single drink?").

    Time frame: Friday of week 1

  18. Alcohol Demand as assessed by the Brief Assessment of Alcohol Demand (BAAD) questionnaire

    Alcohol demand will be assessed via the Brief Assessment of Alcohol Demand (BAAD), a 3-item questionnaire ("If drinks were free, how many would have?", "What is the maximum total amount you would spend on drinking?"; and "What is the maximum you would pay for a single drink?").

    Time frame: Friday of week 2

  19. Delay discounting for alcohol as assessed by a computerized task

    Delay discounting will be assessed for both money and alcohol using a computerized task at weekly clinic visits. Delays will range from 1 day to 25 years, and monetary values will range from $0 to $1,000. In the case of alcohol discounting, the unit of alcohol (e.g., bottle, shot, glass, etc.) and cost of alcohol will be individually assessed in order to present choices that are monetarily equivalent to the money discounting task.

    Time frame: baseline

  20. Delay discounting for alcohol as assessed by a computerized task

    Delay discounting will be assessed for both money and alcohol using a computerized task at weekly clinic visits. Delays will range from 1 day to 25 years, and monetary values will range from $0 to $1,000. In the case of alcohol discounting, the unit of alcohol (e.g., bottle, shot, glass, etc.) and cost of alcohol will be individually assessed in order to present choices that are monetarily equivalent to the money discounting task.

    Time frame: Friday of week 1

  21. Delay discounting for alcohol as assessed by a computerized task

    Delay discounting will be assessed for both money and alcohol using a computerized task at weekly clinic visits. Delays will range from 1 day to 25 years, and monetary values will range from $0 to $1,000. In the case of alcohol delay discounting, the unit of alcohol (e.g., bottle, shot, glass, etc.) and cost of alcohol will be individually assessed in order to present choices that are monetarily equivalent to the money discounting task.

    Time frame: Friday of week 2

  22. Delay Discounting for money as assessed by a computerized task

    Delay discounting will be assessed for both money and alcohol using a computerized task at weekly clinic visits. Delays will range from 1 day to 25 years, and monetary values will range from $0 to $1,000.

    Time frame: baseline

  23. Delay Discounting for money as assessed by a computerized task

    Delay discounting will be assessed for both money and alcohol using a computerized task at weekly clinic visits. Delays will range from 1 day to 25 years, and monetary values will range from $0 to $1,000.

    Time frame: Friday of week 1

  24. Delay Discounting for money as assessed by a computerized task

    Delay discounting will be assessed for both money and alcohol using a computerized task at weekly clinic visits. Delays will range from 1 day to 25 years, and monetary values will range from $0 to $1,000.

    Time frame: Friday of week 2

  25. Alcohol use as assessed by self-report

    Self-reported drinks per day for the past week

    Time frame: baseline

  26. Alcohol use as assessed by self-report

    Self-reported drinks per day for the past week

    Time frame: Friday of week 1

  27. Alcohol use as assessed by self-report

    Self-reported drinks per day for the past week

    Time frame: Friday of week 2

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03398252
Lead sponsor
The University of Texas Health Science Center, Houston
Responsible party
Jin Ho Yoon (Assistant Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Jan 12, 2018
Start date
May 12, 2022 (estimated)
Primary completion
Oct 1, 2023 (estimated)
Completion
Oct 1, 2023 (estimated)
Last update
Sep 1, 2022

Study contacts

Jin Ho Yoon, PhD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion